4-tert-butyl-cyclohexanecarboxylic acid [4-(4-acryloylamino-piperidine-1-sulfonyl)-phenyl]-amide | 1414967-24-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4-tert-butyl-cyclohexanecarboxylic acid [4-(4-acryloylamino-piperidine-1-sulfonyl)-phenyl]-amide
• 英文别名: 4-tert-butyl-N-[4-[4-(prop-2-enoylamino)piperidin-1-yl]sulfonylphenyl]cyclohexane-1-carboxamide
• CAS: 1414967-24-0
• 化学式: C₂₅H₃₇N₃O₄S
• 分子量: 475.652
• InChiKey: BVQFPPCQSUHJOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Prime Michael

  公开号：US20120302539A1

  公开（公告）日：2012-11-29

  Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

  本文提供了某些化合物和药用盐。还提供了包含至少一种化合物或药用盐以及一个或多个药用载体的药物组合物。描述了治疗对转谷氨酰胺酶TG2活性抑制敏感的某些疾病状态的方法。这些疾病状态包括亚型汉廷顿病等神经退行性疾病。还描述了治疗方法，包括单独使用至少一种化合物或药用盐作为单一活性剂或与一个或多个其他治疗剂结合使用至少一种化合物或药用盐。
• US8889716B2
  申请人：——

  公开号：US8889716B2

  公开（公告）日：2014-11-18